24/7 Market News Snapshot 10 June, 2025 – EVOGENE LTD. (NASDAQ:EVGN)

June 10, 2025

DENVER, Colo., 10 June, 2025 (www.247marketnews.com) – (NASDAQ:EVGN) are discussed in this article.
Evogene Ltd. has recently gained significant market attention, with its stock price soaring to $2.771, marking an extraordinary increase of 145.22% from the previous close of $1.130. This price surge, supported by a substantial trading volume of 5.91 million shares, reflects robust investor interest and strong market sentiment. Technical indicators suggest a sustained upward trajectory for the company, prompting traders to closely monitor developments throughout the trading day.

In conjunction with this impressive market performance, Evogene has unveiled its generative AI foundation model, version 1.0, designed specifically for small molecule design. This innovative model, developed in collaboration with Google Cloud, significantly enhances Evogene’s ChemPass AI platform, promising transformative advancements in the pharmaceutical and agricultural sectors. By overcoming the limitations of traditional sequential approaches to molecule development, the generative AI model enables simultaneous consideration of various complex requirements, facilitating the creation of unique molecular structures.

The model’s ability to identify novel small molecules with approximately 90% precision sets a new benchmark in the field, vastly surpassing conventional methodologies. It operates on an extensive dataset of around 38 billion molecular structures, leveraging Google Cloud’s advanced AI capabilities to ensure scalability and efficiency in future innovations.

Ofer Haviv, President and CEO of Evogene, highlighted the pivotal importance of this development, stating that it will dramatically enhance the ability to generate novel molecules that fulfill rigorous performance standards while creating valuable intellectual property.

Looking ahead, Evogene is already progressing toward version 2.0 of the AI foundation model, which aims to further refine multi-parameter optimization features tailored for distinct therapeutic and agricultural applications. The company is actively seeking partnerships within the pharmaceutical and agricultural fields to harness the revolutionary potential of its ChemPass AI platform in next-generation product development.

Related news for (EVGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.